Combination Targeted Therapy with Lenvatinib and Pembrolizumab in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers

By sjmartinez • June 27, 2024

French JD, Haugen BR, Worden FP, Bowles DW, Gianoukakis AG, Konda B, Dadu R, Sherman EJ, McCue S, Foster NR, Nikiforov YE, Farias TDJ, Norman PJ, Wirth LJ. Combination Targeted Therapy with Lenvatinib and Pembrolizumab in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers. Clin Cancer Res. 2024 Jun 26. doi: 10.1158/1078-0432.CCR-23-3417. Epub ahead of print. PMID: 38922338.

Tags: Endocrinology, Harbor UCLA, Publications

Related Posts

Establishing a core outcome set for creatine transporter deficiency and guanidinoacetate methyltransferase deficiency

Nasseri Moghaddam Z, Reinhardt EK, Thurm A, Potter BK, Smith M, Graham C, Tiller BH, Baker SA, Bilder DA, Bogar R, Britz J, Cafferty R,[...]

The protein deacetylase SIRT2 exerts metabolic control over adaptive Beta cell proliferation

Wortham M, Ramms B, Zeng C, Benthuysen JR, Sai S, Pollow DP, Liu F, Schlichting M, Harrington AR, Liu B, Prakash TP, Pirie EC, Zhu[...]

Diesel exhaust induces gut microbiome dysbiosis and reduced fecal acetate: Role of acetate supplementation

Gupta R, Chang C, Vergnes L, Sulaiman D, Yin F, Stewart JA, Mehrabian M, Kaufman JD, Jacobs JP, Lusis AJ, Reue K, Rosenfeld ME, Araujo[...]